Research Article

Benefits of On-X Mitral Valve Replacement in Cases of Infective Endocarditis

Table 7

Pre-operative and post-operative echocardiographic variables in each of the two study groups.

Pre-operative periodEarly post-operative periodLate post-operative period values
Pre- vs. EarlyPre- vs. LateEarly vs. Late

On-X group
LAD (mm)43.3 ± 13.439.9 ± 11.438.2 ± 10.80.52090.10870.5209
LVDd (mm)52.6 ± 4.745.5 ± 5.443.6 ± 6.50.03240.00310.2828
LVDs (mm)31.2 ± 5.131.1 ± 4.627.6 ± 4.30.96870.05990.1573
LVEF (%)69.6 ± 7.758.7 ± 8.866.3 ± 7.40.04500.36480.1213
TR-PG (mmHg)30.1 ± 10.918.3 ± 6.217.5 ± 5.20.01640.00080.6377
E/e22.4 ± 11.727.1 ± 10.530.1 ± 8.60.54970.54970.5497
MV peak v (m/s)1.6 ± 0.31.7 ± 0.21.5 ± 0.30.72700.73580.0255
MV max PG (mmHg)11.1 ± 7.413.7 ± 5.49.7 ± 4.00.57190.57190.0019
MV mean PG (mmHg)4.9 ± 5.05.3 ± 2.53.6 ± 1.20.88590.83390.0485
Effective orifice area (cm2)3.1 ± 0.82.8 ± 0.70.1680
Indexed effective orifice area (cm2/m2)2.0 ± 0.51.8 ± 0.50.1602

SJM group
LAD (mm)48.2 ± 7.545.7 ± 8.550.1 ± 10.90.25840.40610.0120
LVDd (mm)54.3 ± 7.650.4 ± 6.749.0 ± 8.00.00440.00820.3703
LVDs (mm)35.2 ± 6.336.1 ± 6.431.7 ± 7.30.39140.06190.0211
LVEF (%)65.3 ± 6.454.8 ± 10.664.6 ± 9.60.00130.80200.0013
TR-PG (mmHg)34.8 ± 19.022.4 ± 5.226.9 ± 9.60.03710.24800.0740
E/e19.7 ± 7.727.4 ± 7.532.1 ± 10.80.53330.20520.5333
MV peak v (m/s)1.7 ± 0.41.8 ± 0.41.9 ± 0.40.66780.66780.6747
MV max PG (mmHg)11.7 ± 4.712.7 ± 5.714.8 ± 5.60.75430.69590.6959
MV mean PG (mmHg)4.0 ± 1.85.4 ± 1.85.1 ± 5.80.31570.44230.5156
Effective orifice area (cm2)2.7 ± 0.82.2 ± 0.50.3652
Indexed effective orifice area (cm2/m2)1.8 ± 0.71.4 ± 0.40.2324

Values are mean ± SD. vs. On-X valve. LAD left atrial diameter, LVDd left ventricular end-diastolic diameter, LVDs left ventricular end-systolic diameter, LVEF left ventricular ejection fraction, MV mitral valve, SJM St. Jude Medical, TR-PG tricuspid regurgitation pressure gradient.